Shippeo Launches Second Edition of Visibility Now!, the Premier Event for Supply Chain & Transportation Visibility
10.11.2021 11:15:00 EET | Business Wire | Press release
Shippeo, a global leader and European specialist in real-time transportation visibility, has announced the second edition of its customer community event Visibility Now! in partnership with Savoye, TESISQUARE®, and Siemens Digital Logistics. The hybrid event will take place both online and in-person in Paris on November 17 and offer a unique experience for all participants no matter where they are. From keynotes to customer testimonials and workshops and expert sessions, participants will have the chance to discover product insights and benefit from the expert’s points of view.
With covid border restrictions, container and driver shortages as well as the recent Suez Canal obstruction, now is the time for organizations to build resilient supply chains and visibility as a key enabler.
The event will include speakers from leading international organizations who will share their experiences on working with visibility solutions, outlining the critical roles they play in their digital transformation initiatives, and covering topics such as supply chain automation, global supply chain management, customer-centric approach and product innovation. Participants will have the opportunity to:
- Hear industry leaders discuss their experiences and best practices, including speakers from Renault Group, Coca-Cola HBC, DHL Freight, Nexans, Leroy Merlin, Philip Morris International, and Magnus Logistics
- Listen to top experts covering the latest trends, innovations, and guidelines to ensure transportation visibility project success such as Dr. John Gattorna, Siemens Digital Logistics, Savoye and TESISQUARE®
- Enjoy complimentary access to exclusive recorded sessions to dive deeper into trending topics on supply chain management and visibility
- Meet and engage with Shippeo’s team, alongside other Shippeo users and industry peers throughout the day
Global Supply Chain thought leader, Dr. John Gattorna, will share insights on designing future supply chains with embedded resilience, the challenges of operating global supply chain networks, and embracing multi-modal transportation as an integral part of future supply chains. He will also touch on the future role of 3PLs and 4PLs as genuine partners in the extended supply chain.
The event will include a live 90-minute plenary live show, broadcast from Paris in a dynamic and interactive format where participants will discover the latest insights, trends, and innovations related to supply chain and transportation visibility across a number of industry sectors. Several workshops and expert sessions will be held on demand for a deep dive into trending topics and best practices. These interactive workshops will provide an opportunity for participants to interact with other market leaders facing similar challenges and hear more about the latest news, insights, and product innovations in supply chain and transportation visibility from Shippeo experts.
“In the midst of supply chain disruptions, businesses have come to realize the value of real-time visibility and the need to take action, and further engage in digital transformation processes. We’re delighted to showcase the must-attend transportation visibility event and offer participants a place where they can hear from top industry experts, interact with other shippers, carriers, and logistics service providers from across the ecosystem to share and discover new ways to leverage visibility,” says Lucien Besse, COO of Shippeo.
The live show will stream from 1.30 pm on Wednesday 17th November. More information about the agenda, speakers, and how to register for the free event is available at shippeo.com/visibilitynow
About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 850+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 25 million shipments per year across 74 countries. Learn more at www.shippeo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005610/en/
Contact information
Audrey Emanuel, audrey.emanuel@shippeo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom